Albiglutide: a unique GLP-1 receptor agonist

References

• Xu X, Vugmeyster Y. Challenges and opportunities in absorption, distribution, metabolism, and excretion studies of therapeutic biologics. AAPS J. 2012;14:781–791. DOI:10.1208/s12248-012-9388-8.
   PubMed Web of Science ®Google Scholar
• Vugmeyster Y, Harrold J, Xu X. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. AAPS J. 2012;14:714–727. DOI:10.1208/s12248-012-9385-y.
   PubMed Web of Science ®Google Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153–165. DOI:10.1016/j.cmet.2006.01.004.
   PubMed Web of Science ®Google Scholar
• Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–1439. DOI:10.1152/physrev.00034.2006.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Asa S. Glucagon gene expression in vertebrate brain. J Biol Chem. 1988;263:13475–13478.
   PubMed Web of Science ®Google Scholar
• Jin SL, Han VK, Simmons JG, et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, glicentin in the rat brain: an immunocytochemical study. J Comp Neurol. 1988;271:519–532. DOI:10.1002/cne.902710405.
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Tang-Christensen M, Holst JJ, et al. Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience. 1997;77:257–270. DOI:10.1016/S0306-4522(96)00434-4.
   PubMed Web of Science ®Google Scholar
• Larsen PJ, Holst JJ. Glucagon-Related Peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept. 2005;128:97–107. DOI:10.1016/j.regpep.2004.08.026.
   PubMedGoogle Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.
   PubMedGoogle Scholar
• Gautier J, Fetita S, Sobngwi E, et al. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 2005;31:233–242. DOI:10.1016/S1262-3636(07)70190-8.
   PubMed Web of Science ®Google Scholar
• Gallwitz B. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass. Diabetes Technol Ther. 2005;7:651–657. DOI:10.1089/dia.2005.7.651.
   PubMedGoogle Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–957.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Heimesaat MM, Orskov C, et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91:301–307. DOI:10.1172/JCI116186.
   PubMed Web of Science ®Google Scholar
• Little TJ, Pilichiewicz AN, Russo A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. Diabetes Care. 2013;36:1396–1405. DOI:10.2337/dc12-1609.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol Endocrinol Metab. 1996;271:E458–E464.
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab. 2003;88:220–224. DOI:10.1210/jc.2002-021053.
   PubMed Web of Science ®Google Scholar
• Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46–52.DOI:10.1007/BF02427280.
   PubMed Web of Science ®Google Scholar
• Holst J, Christensen M, Lund A, et al., Regulation of glucagon secretion by incretins. Diabetes Obes Metab. 13(Suppl. 1): 89–94. 2011. DOI:10.1111/j.1463-1326.2011.01452.x.
   PubMed Web of Science ®Google Scholar
• Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015;63:109–134. DOI:10.1177/2042018815580257.
   Web of Science ®Google Scholar
• Neumiller J, Campbell R. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Ann Pharmacother. 2009;43:1433–1444. DOI:10.1345/aph.1L704.
   PubMed Web of Science ®Google Scholar
• Norris S, Lee N, Thakurta S, et al. Exenatide efficacy and safety: a systematic review. Diabet Med. 2009;26:837–846. DOI:10.1111/j.1464-5491.2009.02790.x.
   PubMed Web of Science ®Google Scholar
• Petersen A, Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013;6:217–231. DOI:10.2147/DMSO.S45379.
   PubMedGoogle Scholar
• Trujillo J, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48:1494–1501. DOI:10.1177/1060028014545807.
   PubMed Web of Science ®Google Scholar
• Gurung T, Shyangdan DS, O’Hare JP, et al. A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab Syndr Obes. 2015;8:363–386. DOI:10.2147/DMSO.S34418.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Balas B, Charbonnel B. et al.; T-emerge 2 Study Group. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial. Diabetes Care. 2013;36:498–504. DOI:10.2337/dc12-0709
   PubMed Web of Science ®Google Scholar
• Green BD, Gault VA, Irwin N, et al. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1. Biol Chem. 2003;384:1543–1551. DOI:10.1515/BC.2003.171.
   PubMed Web of Science ®Google Scholar
• Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature. 1996;379:69–72. DOI:10.1038/379069a0.
   PubMed Web of Science ®Google Scholar
• Steinert RE, Schirra J, Meyer-Gerspach AC, et al. Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr. 2014;100:514–523. DOI:10.3945/ajcn.114.083246.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight. J Clin Invest. 2014;124:4223–4226. DOI:10.1172/JCI78371.
   PubMed Web of Science ®Google Scholar
• Gedulin BR, Nikoulina SE, Smith PA, et al. Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology. 2005;146:2069–2076. DOI:10.1210/en.2004-1349.
   PubMed Web of Science ®Google Scholar
• Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785–790. DOI:10.2337/db13-0893.
   PubMed Web of Science ®Google Scholar
• Lorenz M, Pfeiffer C, Steinsträsser A, et al. Effects of lixisenatide once daily on gastric emptying in type 2 diabetes–relationship to postprandial glycemia. Regul Pept. 2013;185:1–8. DOI:10.1016/j.regpep.2013.04.001.
   PubMedGoogle Scholar
• Astrup A, Carraro R, Finer N. et al.; NN8022–1807 investigators. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes. 2012;36:843–854. DOI:10.1038/ijo.2011.158
   PubMed Web of Science ®Google Scholar
• Lean M, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes. 2014;38:689–697. DOI:10.1038/ijo.2013.149
   PubMed Web of Science ®Google Scholar
• Gupta V. Glucagon-like peptide-1 analogues: an overview. Indian J Endocrinol Metab. 2013 May-Jun;17(3):413–421. DOI:10.4103/2230-8210.111625.
   PubMedGoogle Scholar
• Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377–1397. DOI:10.3390/polym3031377.
   PubMed Web of Science ®Google Scholar
• DeYoung MB, MacConell L, Sarin V, et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011 Nov;13(11):1145–1154. DOI:10.1089/dia.2011.0050.
   PubMed Web of Science ®Google Scholar
• Syed YY, McCormack PL. Exenatide extended-release: an updated review of its use in type 2 diabetes mellitus. Drugs. 2015;75(10):1141–1152. DOI:10.1007/s40265-015-0420-z.
   PubMed Web of Science ®Google Scholar
• Grimm M, Han J, Weaver C, et al. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the duration trials. Postgrad Med. 2013;125:47–57. DOI:10.3810/pgm.2013.05.2660.
   PubMed Web of Science ®Google Scholar
• MacConell L, Gurney K, Malloy J, et al. Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes Metab Syndr Obes. 2015;8:241–253. DOI:10.2147/DMSO.S77290.
   PubMed Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296. DOI:10.1002/dmrr.1080.
   PubMed Web of Science ®Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database issue):D668–D672. DOI:10.1093/nar/gkj067.
   PubMed Web of Science ®Google Scholar
• Jimenez-Solem E, Rasmussen MH, Christensen M, et al. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12:790–797.
   PubMed Web of Science ®Google Scholar
• Dungan K, Povedano S, Forst T. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014;384:1349–1357. DOI:10.1016/S0140-6736(14)60976-4.
   PubMed Web of Science ®Google Scholar
• Sleep D. Albumin and its application in drug delivery. Expert Opin Drug Deliv. 2015;12:793–812. DOI:10.1517/17425247.2015.993313.
   PubMed Web of Science ®Google Scholar
• Bush MA, Matthews JE, De Boever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab. 2009;11:498–505. DOI:10.1111/j.1463-1326.2008.00992.x.
   PubMed Web of Science ®Google Scholar
• Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting Glucagon-Like Peptide-1 mimetic, in patients with type 2 diabetes. J Clin Endocrin & Metab. 2008;93:4810–4817. DOI:10.1210/jc.2008-1518
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Assessment report, Eperzan, International non-proprietary name: albiglutide, Procedure No. EMEA/H/C/002735/0000 23 January 2014 EMA/CHMP/705417/2013 Committee for Medicinal Products for Human Use (CHMP).
   Google Scholar
• Drug Approval Package. FDA Tanzeum (Albiglutide) Injection Company: GlaxoSmithKline LLC Application No.: 125431 Approval Date: 4/15/2014.
   Google Scholar
• Young MA, Wald JA, Matthews JE, et al. Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgrad Med. 2014;126:84–97. DOI:10.3810/pgm.2014.11.2836.
   PubMed Web of Science ®Google Scholar
• Reusch J, Stewart M, Perkins C, et al. Efficacy and safety of once weekly GLP-1 receptor agonist albiglutide (HARMONY 1): 52 week primary endpoint results from a randomized, double-blind, placebo controlled, trial in patients with type 2 diabetes mellitus not controlled on pioglitazone ± metformin. Diabetes Obes Metab. 2014;16:1257–1264.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59:266–274. DOI:10.1007/s00125-015-3795-1.
   PubMed Web of Science ®Google Scholar
• Ahrén B, Johnson SL, Stewart M. et al.; HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141–2148. DOI:10.2337/dc14-0024
   PubMed Web of Science ®Google Scholar
• Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57:2475–2484. DOI:10.1007/s00125-014-3360-3.
   PubMed Web of Science ®Google Scholar
• Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17:179–187. DOI:10.1111/dom.12414.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Fonseca VA, Gross JL, et al.; Harmony 6 Study Group. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–2325. DOI:10.2337/dc14-0001
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck MA, Barnett AH, et al.; HARMONY 7 study group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–297. DOI:10.1016/S2213-8587(13)70214-6
   PubMed Web of Science ®Google Scholar
• Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37:2723–2730. DOI:10.2337/dc13-2855.
   PubMed Web of Science ®Google Scholar
• Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:82–90. DOI:10.1111/dom.12398
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–156. DOI:10.1053/j.gastro.2011.02.018.
   PubMed Web of Science ®Google Scholar
• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs — FDA and EMA assessment. N Engl J Med. 2014;370:794–797. DOI:10.1056/NEJMp1314078
   PubMed Web of Science ®Google Scholar
• Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703. DOI:10.1016/S2213-8587(15)00233-8
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K. et al.; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250. DOI:10.1016/S0140-6736(08)61206-4
   PubMed Web of Science ®Google Scholar
• Bentley-Lewis R, Aguilar D, Riddle MC. et al.; ELIXA Investigators. Rationale, design, and evaluation of LIXisenatide in acute coronary syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015;169:631–638. DOI:10.1016/j.ahj.2015.02.002
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128. DOI:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med.2016 Jul 28;375(4):311–322. DOI:10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf. 2013;12:195–207. DOI:10.1517/14740338.2013.770470.
   PubMed Web of Science ®Google Scholar